Fig 1.
Population pyramid with the age and gender distribution of the 106 patients with Chagas disease acquired by the oral route, 2007–2017, Chacao, Caracas, Venezuela.
Table 1.
Absolute number of evaluated patients with oral Chagas disease according to age group before and after the first treatment, Chacao, Caracas, Venezuela 2007–2017.
Fig 2.
Descriptive flowchart of the complete follow-up of patients with Chagas disease acquired by the oral route, Chacao, Caracas, Venezuela, 2007–2017.
Table 2.
Prevalence of clinical findings and ECG/Holter abnormalities in the follow-up of 106 patients with oral Chagas disease, Chacao, Caracas, Venezuela 2007–2017.
Table 3.
Prevalence of significant associations between the pre and post-treatment clinical and ECG/Holter findings in 106 patients with acute Chagas disease acquired by the oral route, Chacao, Caracas, Venezuela, 2007–2017.
Fig 3.
Post-treatment ECG/Holter findings with statistical significance according to age of children with oral Chagas disease, Chacao, Caracas, Venezuela, 2008–2017 (Abnormalities without statistical significance were not shown).
Table 4.
Altered echocardiographic findings and cardiothoracic ratio in the follow-up in patients with Chagas disease acquired by the oral route, Chacao, Caracas, Venezuela, 2007–2017.
Table 5.
Cumulative incidence of clinical and ECG/Holter findings after treatment in 106 patients with Chagas disease orally acquired, Chacao, Caracas, Venezuela, 2008–2017.
Fig 4.
Definitive persistence or disappearance of clinical (A) or ECG/Holter (B) findings after the first treatment 2008–2017, in patients with Chagas disease acquired by the oral route, Chacao, Caracas, Venezuela (p value according to the McNemar χ2 test comparing persistence versus disappearance).